Novo Nordisk’s Guidance Raise Wasn’t Enough: The Lingering Challenges That Drove Shares Lower
Despite Q2 beat and raise, Novo shares dropped on flat 2026 outlook, DKK 6.3B impairment, ZEUS failure and fierce Lilly competition.
/ 107 items
#NVO↓
BioAge Labs Plunges Over 60% After Novo’s ZEUS Trial Failure — Citi Says the Sell-Off Is Overdone
BioAge Labs shares fell over 60% after Novo Nordisk’s ZEUS trial failed to cut MACE. Citi says the sell-off is excessive despite negative ASCVD impact.
Novo Nordisk’s Anti-Inflammatory Drug Fails Key Heart Trial
Novo Nordisk’s ziltivekimab failed to reduce major cardiovascular events in the late-stage ZEUS trial of high-risk patients.
Lilly’s Next Obesity Blockbuster Retatrutide on Track for 2027 Approval After Five Positive Phase 3 Studies
Analysts say Lilly’s retatrutide, heading for 2027 FDA filing after strong trials, could hit $3.8B sales by 2030 and help keep its edge over Novo Nordisk.
Novo’s Wegovy Pill Crushes Lilly’s Foundayo in Early Weight-Loss Battle
Novo Nordisk’s Wegovy pill is dominating early sales with 8x more prescriptions than Eli Lilly’s Foundayo.
Avere Therapeutics Debuts on Nasdaq Backed by Ex-Akero Leaders Behind Novo Nordisk Acquisition
The company just went public via a $320M reverse merger with NextCure and is advancing a promising once-weekly oral IL-23 inhibitor for psoriasis and ulcerative colitis.